GANX - Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

• Gain Therapeutics has a market cap of just $84m. The biotech is developing small molecules to treat rare genetic diseases.
• The company uses a proprietary drug discovery engine, SEE-Tx, which targets allosteric binding sites, and misfolded proteins - approaches previously validated either by trial data or major investment.
• Gain has not yet had an IND accepted by the FDA, but targets include GM1 Gangliosidosis, Parkinson's, and Gaucher Disease.
• There are areas of high unmet need and competitive fields, but Gain does at least have some promising preclinical data.
• The $7 per share entry point feels cheap to me, with numerous upcoming catalysts, an experienced management team and Board, and oral availability all plus points.

For further details see: